Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial

NCT00150332 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00150332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00150332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2003
Completion date
January 31, 2006
Enrollment
24 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

infections, nosocomial